Toth Financial Advisory Corp Purchases 1,429 Shares of Johnson & Johnson (NYSE:JNJ)

Toth Financial Advisory Corp grew its position in Johnson & Johnson (NYSE:JNJ) by 2.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,799 shares of the company’s stock after acquiring an additional 1,429 shares during the quarter. Johnson & Johnson accounts for 1.3% of Toth Financial Advisory Corp’s portfolio, making the stock its 20th biggest holding. Toth Financial Advisory Corp’s holdings in Johnson & Johnson were worth $10,415,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of JNJ. Lantz Financial LLC grew its stake in shares of Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after buying an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. purchased a new position in Johnson & Johnson in the fourth quarter worth about $453,000. Horan Securities Inc. grew its position in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC increased its stake in Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after acquiring an additional 1,271 shares during the last quarter. Finally, State of Wyoming raised its position in Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after purchasing an additional 10,279 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $155.02 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market cap of $372.99 billion, a PE ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a fifty day moving average price of $153.59 and a 200-day moving average price of $153.67.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. Barclays cut their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Wednesday, April 16th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.